Skip to main content

Table 2 Shows baseline characteristics of enrolled patients in included studies

From: Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

Study ID

Drug

N

Age (Mean ± SD)

Sex (male) n (%)

Race (White) n

MMSE score (Mean ± SD)

AChEI or memantineuse, n (%)

APOE ε4 status carrier no. (%)

ADAS-cog score (Mean ± SD)

DAD score (Mean ± SD)

SSalloway et al., 2009 [13]

Placebo

107

67.9 ± 8.8

43 (40.2)

102 (95.3)

20.7 ± 3.1

103 (96.3)

74 (69.8)

…..

….

Bapineuzumab

122

70.1 ± 9.6

661 (50.0)

118 (96.7)

20.9 ± 3.2

116 (95.1)

72 (60.5)

…..

…..

Black et al., 2010 [15]

Placebo

8

69.8 ± 10.7

11 (12.5)

5 (62.5)

20.8

.....

.....

.....

.....

Bapineuzumab 0.5 mg/kg

6

74.67 ± 5.65

33 (50)

4 (66.67)

21.8

.....

.....

.....

.....

Rinne et al., 2010 [14]

Placebo

7

70 ± 8·81

33 (43)

7 (100)

22·29 ± 2·69

7 (100)

5 (71)

19·19 ± 5·27

93·78 ± 8·24

Bapineuzumab

19

67·26 ± 8·60

311 (57.9)

19 (100)

21·00 ± 2·33

19 (100)

12 (63)

22·26 ± 7·65

84·38 ± 11·95

Salloway et al., 2014 (Carrier) [16]

Placebo

432

72.3 ± 8.4

190 (44)

420 (97.2)

20.7 ± 3.2

400 (92.6)

432 (100)

23.9 ± 9.5

79.4 ± 18.9

Bapineuzumab 0.5 mg/kg

658

72.0 ± 8.0

300 (45.6)

624 (94.8)

20.8 ± 3.1

606 (92.1)

658 (100)

23.5 ± 9.4

80.9 ± 17.3

Salloway et al., 2014 (Non-Carrier) [16]

Placebo

493

71.9 ± 10.1

245 (49.7)

469 (95.1)

21.2 ± 3.2

442 (89.7)

493 (100)

23.5 ± 9.4

80.5 ± 19.2

Bapineuzumab 0.5 mg/kg

314

73.1 ± 9.3

149 (47.5)

298 (94.9)

21.2 ± 3.4

281 (89.5)

314 (100)

22.4 ± 9.7

80.0 ± 18.1

Bapineuzumab 1 mg/kg

307

73.5 ± 9.1

132 (42.9)

292 (95.1)

21.2 ± 3.3

278 (90.6)

307 (100)

22.2 ± 10

80.4 ± 18.8

Arai et al., 2015 [17]

Placebo

8

68.8 ± 8.9

4 (50)

.....

20.6 ± 3.0

.....

.....

.....

.....

Bapineuzumab 0.5 mg/kg

6

72.2 ± 8.4

5 (83.3)

.....

21.0 ± 3.6

.....

.....

.....

.....

Bapineuzumab 1 mg/kg

6

72.2 ± 10.9

3 (50)

.....

21.0 ± 4.6

.....

.....

.....

.....

  1. Abbreviations: AChEI Acetyl-Choline Esterase Inhibitor, ADAS-Cog 11 Alzheimer disease assessment scale - Cognitive subscale 11 items, DAD Disability assessment scale, MMSE Mini-Mental State Examination